Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 1 · 100%

Vasomotor toxicity · women with hormone‐sensitive advanced breast cancer

Fulvestrant showed no clear difference in vasomotor toxicity compared with other endocrine treatment (high certainty).

1 finding from 1 review

Fulvestrant for hormone‐sensitive metastatic breast cancer 2017 · Cochrane Headline outcomes only
RR 1.02 [0.89, 1.18]
8 studies · 3544 participants
High